Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320682 | 0.83 | ALDH1A1 (0.45) | ALDH1A1KMT2ACYP2C19 | |
| SCHEMBL304787 | 0.76 | CYP2C19 (0.31) | KMT2ACYP2C19 | |
| SCHEMBL4736565 | 0.76 | HDAC6 (0.36) | — | |
| SCHEMBL304788 | 0.75 | ALDH1A1 (0.65) | ALDH1A1KMT2ACYP2C19 | |
| SCHEMBL11986240 | 0.75 | ALDH1A1 (0.38) | ALDH1A1KMT2ACYP2C19 | |
| SCHEMBL1216481 | 0.75 | — | — | |
| SCHEMBL5964972 | 0.75 | ALDH1A1 (0.38) | ALDH1A1KMT2ACYP2C19 | |
| SCHEMBL632730 | 0.74 | CYP2C19 (0.36) | ALDH1A1KMT2ACYP2C19 | |
| SCHEMBL9790004 | 0.74 | SOAT1 (0.50) | ALDH1A1KMT2ACYP2C19 | |
| SCHEMBL6896474 | 0.74 | PTGS1 (0.42) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324273-B2 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. | 2008-07-17 | — | — | US | disclosed |
| WO-2008079387-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | COMT, PARK7, DDT | ALDH1A1 636/4885KMT2A 1661/4885CYP2C19 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.